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Vpu and the C-terminal peptide of Gag (p6) are both HIV-1-encoded proteins that augment the release of virus particles
from cells. We examined the functional relationship between these proteins and their activities during particle release. Our
results indicate that efficient HIV-1 particle release from HeLa and Jurkat cells depends on the presence of Vpu. However,
Vpu is dispensable for efficient release from Cos cells. In contrast, p6 is required for efficient release from Cos cells but
not from Jurkat or HeLa cells. These data suggest that Vpu and p6 have distinct activities in virus exit from different cell
lines. Intracellular proteolytic processing of Gag precursor protein is more complete in Cos cells than in HeLa cells. However,
this processing has little or no effect on Vpu- or p6-mediated particle release. p6 is required for incorporation of yet another
virus protein (Vpr) into cells but our data suggest that Vpr plays no role in p6-dependent particle release. Vpu also facilitates
the degradation of CD4 in virus producing cells but, in contrast to particle release, the ability of Vpu to facilitate the
degradation of CD4 is not cell line-dependent. q 1996 Academic Press, Inc.
All replication competent retroviruses contain gag, pol, the release of retroviruses both closely (HIV-2 and visna
virus) and distantly related (murine leukemia virus orand env genes. In the case of the oncovirus subfamily,
these three genes are sufficient in trans for replication. MLV) to HIV-1. Vpu has been shown to interact with and
specifically induce the degradation of CD4 (11, 12, 14).However, lentiviruses, spumaviruses, and the human T-
cell leukemia virus (HTLV) and its relatives contain auxil- Taken together, these data do not unequivocally demon-
strate that Vpu action is mediated via cellular factors, butiary genes along with the signature gag, pol, and env
genes. Human immunodeficiency virus Type 1 (HIV-1) is the data are consistent with this possibility.
The retroviral core is composed principally of Gag anda member of the lentivirus subfamily and contains at
least six accessory genes. Gag–Pol proteins. However, in HIV-1 substantial
amounts of a protein encoded by a second auxillary geneOne of these accessory genes, viral protein U (vpu),
is unique to HIV-1 and contains no homolog even in (vpr) are also found in particles (15). Many studies have
demonstrated that expression of Gag alone is sufficientrelated lentivirus species such as human immunodefi-
ciency virus Type-2 (HIV-2) or simian immunodeficiency for the formation and release of immature, noninfectious
virus particles (16). Mature Gag protein is derived fromvirus (SIV). Vpu, an 81-amino-acid, phosphorylated (1, 2),
type I integral membrane protein (3), is not absolutely both the Gag and Gag–Pol polyprotein precursors via
proteolytic cleavage catalyzed by a virally encoded prote-required for HIV-1 replication in cell culture (2, 4, 5). Vpu
has been demonstrated to augment the rate of release ase (PR) (17). In both the type-C and lentiviruses, the
paradigm of particle assembly is that the Gag and Gag –of viral particles from cells (4–7) and acts to degrade
CD4 (8–12), the cellular receptor for HIV-1. Pol precursors accumulate at the cytoplasmic side of
the plasma membrane (18) by way of the hydrophobic,Although individual Vpu molecules appear to interact
with each other (3), there is no evidence for direct interac- myristolated N-terminus (19–21). This aggregation is be-
lieved to increase the local concentration of Gag andtion between Vpu and any other viral proteins. For exam-
ple, attempts to detect a direct interaction between Vpu Gag–Pol proteins leading to intermolecular association
between multiple precursors, the concerted formation ofand gp160 have not been successful (10, 11). Gottlinger
et al. (13) demonstrated that Vpu expression enhances viral cores, and the opportunity for proteolytic processing
(18). Processing can occur both prior to particle release
and following liberation of particles from the cell and is
1 Present address: Department of Microbiology-Immunology, North- not required for efficient virus particle release (17). In the
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tion of efficient virus particle release from cells (24–26).
In contrast to results suggesting a role for p6 in virus
particle release, several studies have indicated that p6
is not required for efficient particle release in a number
of different systems (27 –34). In addition to its role in
particle release p6 is essential, and perhaps sufficient,
for association of Vpr with virus particles (27, 35, 36). It
has also been reported that HIV-1 p6 can functionally
substitute in a late budding function for the Rous sar-
coma virus (RSV) assembly domain 2 region (25).
The fact that the phenotypes of Vpu and p6 mutations
have similar features raises the possibility that both pro-
teins promote particle exit through a common mecha-
nism. However, there is no evidence to support such a
link. The fact that p6 is required for uptake of Vpr into
particles (27, 35, 36) also raises the possibility that Vpr
is necessary for p6-facilitated particle release.
In this study we attempted to determine whether there
is an overt mechanistic connection between the way in
which Vpu and p6 promote the exit of HIV-1 particles.
Moreover, we wanted to see whether ancillary variables
such as cell line, the proteolytic processing of Gag, or
incorporation of Vpr into virus particles might also affect
Vpu- and p6-mediated particle release. The results of
these experiments suggest that there is a fundamental
distinction in the way in which these two proteins pro-
mote virus release.
HeLa cells have proven to be expedient for the exami-
nation of both Vpu-mediated particle release (4) and Vpu-
mediated CD4 degradation (14). However, since the vpu
FIG. 1. Diagram and summary of expression constructs used in thisgene is present in HIV-1 but absent in SIV, it is reason-
study. pWT is a derivative of pNL4-3 that has a deletion in the envable to postulate that Vpu may not be necessary to effi-
gene, rendering virus produced from this expression construct nonin-
ciently produce infectious virus from simian cells. We fectious (7). Vpu0 expression constructs contain an 8-bp insertion to
initially used a trans-complementation strategy (6) to create a frameshift mutation in the vpu gene. p60 expression constructs
contain a base pair substitution which creates a premature stop codonmeasure replication, over a single round of replication,
at amino acid 2 of the p6-coding region of the gag gene. PR0 expressionin the presence and absence of Vpu for virus produced
constructs contain a substitution mutation that changes the asparticfrom Cos cells. Briefly, HIV-1 DNA expression constructs
acid at amino acid 25 (active site) of HIV-1 protease to an arginine. Vpr0
pWT (env0vpu/) or pBG135 (env0vpu0) (Fig. 1) were co- expression constructs contain a substitution mutation that introduces a
transfected into Cos cells along with envelope expres- premature stop codon at amino acid 11 of the Vpr gene. pBG139 ex-
presses the HIV-1 Env-gp and Vpu from the HIV-1 LTR. pBG138 ission constructs that express or lack vpu (pBG138 or
identical to pBG139 except it contains except that it is Vpu0.pBG139, respectively) (Fig. 1). The virus produced by
trans-complementation was then used to infect CD4/-
LTR/b-gal indicator cells (37). Virus produced from the
we examined particle release from CV-1 cells, the pro-initial transfection were capable of only one round of
genitor cell line to Cos. Although the absolute titer fromreplication since the packaged RNA lacked a functional
CV-1 cells was reduced approximately fourfold relativeenv gene. Successful infection events were quantified by
to that from Cos cells, infectious virus production fromscoring b-gal expression following de novo expression of
CV-1 cells was again shown to be Vpu-independent (dataTat from WT or BG135 proviruses. In contrast to previous
not shown).results in which virus was produced from HeLa cells (6),
The titer for virus produced from Cos and CV-1 cellswhen virus was derived from Cos cells the titer was
was similar when Vpu was present or absent. One inter-equivalent in the presence and absence of Vpu expres-
pretation of this observation is that infectious titer wassion (data not shown).
a direct reflection of the efficiency of particle release.Cos cells contain a replication-defective simian virus
However, it was also formally possible that particle re-40 (SV40) mutant that expresses T-antigen. It seemed
lease was still inefficient in the absence of Vpu, but thatunlikely that T-antigen would obviate the need for Vpu,
but we wanted to test this possibility directly. Therefore, those particles that were produced could infect and es-
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trast to the results obtained using Cos cells, and in con-
cordance with the results we obtained using HeLa cells,
the release of p24 from transfected Jurkat cells is en-
hanced approximately 6.5-fold in the presence of Vpu
expression (data not shown).
Unlike Vpu, the C-terminal product of the gag gene
(p6) is found in both HIV-1 and SIV. Since the phenotype
of some p60 mutants is very similar to that of Vpu muta-
tions, and since Vpu appears to be dispensable for effi-
cient particle release from Cos cells, we wanted to deter-
mine whether p6-mediated particle release is also cell
line-dependent. We constructed pMS168, a p60 deriva-
tive of an Env0 molecular clone pWT (Fig. 1), which has
a premature stop codon at the second amino acid posi-
tion of p6. Thus, expression of pMS168 would be ex-
FIG. 2. HIV-1 p24 release from cells transfected with a vpu0 mutant. pected to result in the synthesis of a truncated Gag pre-
Cos cells were mock transfected or transfected with either pBG135
cursor protein with a mass of approximately 49 kDa.(Vpu0) or pWT (Vpu/). Forty-eight hours later the cells were pulse
labeled with L-[35S]methionine for 60 min, followed by a chase with We directly examined the efficiency of particle release
fresh cell culture media for varying times. After 0, 60, 120, and 210 min, from both Cos and HeLa cells in the presence and the
medium was removed and immunoprecipitated using AIDS patient sera absence of p6. Cells were transfected in parallel with
and analyzed on a 15% polyacrylamide gel. In addition, the cells from
pWT (p6/) and pMS168 (p60) and cellular and virion-the 120-min time point were lysed and immunoprecipitated to detect
associated Gag protein was detected and quantified byintracellular levels of p24.
immunoblotting using an anti-Gag serum, a radiolabeled
secondary antibody, and subsequent phosphorimage
tablish proviruses more efficiently than particles gener-
analysis. Expression of gag from pWT resulted in the
ated in the presence of Vpu. To test this possibility, and
intracellular accumulation of the full-length Gag precur-
to examine virus release in a more straightforward way,
sor (pr55gag) as well as fully processed capsid proteinwe performed pulse/chase and immunoprecipitation
(p24gag) in both Cos and HeLa cells (Figs. 3A and 3B).analysis, as previously described (6), on viral protein pro-
Moreover, expression of pMS168 (p60) resulted in theduced from Cos cells transfected with either pBG135
generation of a truncated Gag precursor with an approxi-(vpu0) or pWT (vpu/). Virus-producing cells were pulsed
mate mass of 49 kDa in both cell lines (Figs. 3A and 3B).with L-[35S]methionine for 1 hr and chased with complete
Although fully processed p24 was observed in pMS168-media, and the released viral proteins were collected at
transfected cells, proteolytic processing of the truncatedvarious times after the chase. Viral proteins were de-
Gag derivative was reduced as evidenced by the appear-tected by immunoprecipitation with serum from an AIDS
ance of two intermediate processing products (p41, com-patient, gel electrophoresis, and autoradiography (Fig.
posed of matrix (p17gag) and capsid (p24gag) and p25, a2). The results of this experiment demonstrated that the
penultimate intermediate in the formation of p24) and therate of capsid release was similar whether or not Vpu
reduction of the amount of p24. In concordance withwas expressed. Therefore, the efficiency of particle re-
published work (24) the absence of p6 profoundly im-lease from this simian cell line is actually Vpu-indepen-
peded particle release from Cos cells. However, the lackdent, and infectious titer was indicative of particle pro-
of p6 had little or no effect on particle release from HeLaduction. Furthermore, the data are consistent with the
cells (Fig. 3B), as evidenced by measurement of the totalpossibility that particle release, mediated by Vpu, is cell
Gag-derived products in viruses resulting from transfec-line-dependent.
tion of HeLa cells with pWT or pMS168. This apparentIf particle exit from some cell lines does not require
cell line-dependence of p6-enhanced particle releaseVpu, then what is the role of Vpu in particle egress from
was the opposite of that observed for Vpu-facilitated re-human T-cells? To answer this question we also com-
lease. A summary of the data from several transfectionspared particle release from Jurkat cells in the presence
of pWT and pMS168 into Cos and HeLa cells is providedand the absence of Vpu with that from HeLa and Cos
in Fig. 3C. These data are reported as the relative effi-cells. These three cell lines were transfected with either
ciency of virus particle release and are derived by calcu-pWT (vpu/) or pBG135 (vpu0), and 48 hr posttransfection
lating the ratio of total virion-associated Gag protein andthe cells were metabolically labeled for 1 hr with L-[35S]-
the total cytoplasmic levels of Gag protein. The relativemethionine, chased for 3 hr, and intracellular and virion-
efficiency of virus particle release from pWT is normal-associated p24 were immunoprecipitated. Following
ized to 1.0. We also constructed a double mutant con-electrophoresis, the amount of intracellular and viral p24
was quantified using phosphorimage analysis. In con- taining lesions in both p6 and Vpu (pMS161). The pheno-
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FIG. 3. Immunoblot analysis of cytoplasmic and virion-associated proteins from p6 and Vpr mutant DNAs. Cos (A) or HeLa (B) cells were transfected
with various expression plasmids. Forty-eight hours posttransfection, cytoplasmic proteins were isolated. Medium from cells was subjected to high-
speed centrifugation and viral particles were pelleted through a 20% sucrose cushion. Both cytoplasmic and virion-associated proteins were
separated by SDS–PAGE and transferred to a nitrocellulose membrane. The membrane was probed with a rabbit anti-Gag serum and bound
antibodies were visualized by incubation with an anti-rabbit 35S-conjugated antibody. Gag protein was visualized and quantified by phosphorimage
analysis. The relative ratio of virion-associated to intracellular gag protein for relevant p6/ and p60 virus pairs is presented in C. In each case, the
ratio for the p6/ virus has been normalized to 1.0.
type of this mutant, in HeLa cells, was similar to that of efficiently even in the absence of p6. Jurkat cells were
transfected in parallel with pWT (p6/) or pMS168 (p60)a Vpu mutant (data not shown).
Vpu was necessary for efficient particle release from and particle production was assessed in a manner simi-
lar to that for particle production from Cos and HeLaJurkat cells. Given our results with Cos cells, we wanted
to see whether p6 was also necessary for exit of particles cells. The results of this experiment indicated that, as
with HeLa cells, virus particle release in the absence offrom this T-cell line or whether virus production occurred
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Gag and Gag/Pol polyprotein precursors that are not pro-
teolytically processed.
We transfected Cos cells with either pMS172 (pr0vpu/)
or pMS173 (pr0vpu0) and 48 hr after transfection the cells
were metabolically labeled for 1 hr with L-[35S]-
methionine. Intracellular and extracellular Gag were then
immunoprecipitated after a 3-hr chase period. The results
of this experiment demonstrate that, as expected, the
released viral cores were composed of unprocessed Gag
precursor protein. Further, the proficiency of particle re-
lease from Cos cells was similar in the presence or the
absence of protease activity (data not shown). Thus, the
Vpu-independent release of viral protein occurs even in
the absence of processing and indicates that the vari-
ance in intracellular proteolytic processing of Gag is un-
likely to account for the differential dependence of parti-
cle release on Vpu in Cos and HeLa cells.
We also determined whether lack of Gag processing
affects the phenotype of a p60 virus. We transfected
pMS172 (p6/pr0) and pMS176 (p60pr0) (Fig. 1) in parallel
into Cos and HeLa cells and virus particle release was
FIG. 4. Immunoblot analysis of cytoplasmic and virion-associated monitored as described above. The results of that analy-
proteins from Jurkat cells. Jurkat cells were transfected with the indi-
sis indicated that the absence of processing also hadcated expression constructs. Forty-eight hours posttransfection, cyto-
no effect on p6-enhanced particle release from eitherplasmic proteins were isolated. Medium from cells was subjected to
high-speed centrifugation and viral particles were pelleted through a cell-type (Figs. 3A and 3B). A summary of the data from
20% sucrose cushion. Both cytoplasmic and virion-associated proteins several transfections of pMS172 and pMS176 into Cos
were separated by SDS–PAGE and transferred to a nitrocellulose mem- and HeLa cells is provided in Fig. 3C. These data are
brane. The membrane was probed with a rabbit anti-Gag serum and
reported as the relative efficiency of virus particle releasebound antibodies were visualized by incubation with an anti-rabbit 35S-
and are derived by calculating the ratio of total virion-conjugated antibody. Virus-specific protein was visualized and quanti-
fied by phosphorimage analysis. associated Gag protein and the total cytoplasmic levels
of Gag protein. The relative efficiency of virus particle
release from pMS172 is normalized to 1.0.
p6 (pMS168) was at least as efficient as release in the Transport and exit of type-D retroviruses, such as Ma-
presence of p6 (pWT) (Fig. 4). Thus, Jurkat (or HeLa) and son–Pfizer monkey virus (MPMV), is fundamentally differ-
Cos cells display inverse dependence on Vpu and p6 for ent from that of type-C and lentiviruses. MPMV can repli-
efficient particle release. cate in Cos cells and virus budding is achieved by forma-
The extent of intracellular processing is different in tion of intracellular capsids, the entry of those capsids
HeLa and Cos cells. Intracellular processing of Gag pre- into internal vesicles, and release of virus by exocytosis
cursor protein is extensive in Cos cells; in pulse–chase (38). This mode of release can also be accompanied by
analysis, by 120 min after initiation of the chase, abun- relatively extensive proteolytic processing of Gag. Thus,
dant p24 is observed in cells (Fig. 2). In contrast, analysis we wanted to see whether the primary route of HIV-1 out
of intracellular Gag processing at 120 min using an iden- of Cos cells is via a pathway similar to that used by type-
tical protocol indicates relatively less proteolytic pro- D retroviruses and whether this pathway bypasses the
cessing in HeLa cells (6). Since proteolytic processing need for Vpu.
is an event that temporally overlaps with particle release, To determine whether intracellular core formation oc-
we wanted to determine whether the difference in the curs more efficiently in Cos cells than in HeLa cells we
extent of intracellular proteolytic processing was respon- employed an intracellular capsid formation assay
sible for the cell line-dependence of Vpu and p6. In partic- adapted from Rhee et al. (39). Briefly, Cos or HeLa cells
ular, we wanted to test the possibility that extensive intra- that had been transfected with the pWT were metaboli-
cellular processing obviates the need for Vpu. Therefore, cally labeled with L-[35S]methionine and lysed at various
viral protein was produced in Cos cells, in the presence time points with a Triton X-100 lysis buffer. This lysate
and the absence of Vpu, from a construct containing was then subjected to centrifugation. The supernatant
an amino acid substitution in the active site of the viral and pellet were then independently immunoprecipitated
protease. These constructs, pMS172 (vpu/pr0) and with a rabbit anti-Gag serum and the viral proteins were
pMS173 (vpu0pr0) (Fig. 1) contain or lack an intact vpu separated by 10% SDS–PAGE and analyzed by phos-
phorimage analysis. This analysis indicated that in bothgene, respectively, and would be expected to produce
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see whether CD4 degradation was rapid even in the
absence of Vpu in Cos cells. Thus, we used the method
of Willey et al. (11, 12) to measure intracellular CD4 levels
in the presence and absence of Vpu. In brief, we cotrans-
fected pWT (vpu/) or pBG135 (vpu0), along with pHIV-
CD4 (40) and pHcenvSV (41), into Cos or HeLa cells.
To measure steady-state CD4 levels we then performed
immunoblot analysis on the cell lysates using polyclonal
anti-CD4 antibodies to monitor CD4. The results of this
experiment indicated that Vpu was required for rapid
intracellular degradation of CD4 in both Cos and HeLa
cells (data not shown). Thus, in contrast with particle
release, the data indicate Vpu is able to induce CD4
degradation in Cos cells. This indicates that there is not
a factor(s) in Cos cells that is the equivalent to Vpu.
Moreover, this result is consistent with the notion that
enhancement of particle release and induction of CD4
degradation are discrete, unconnected activities trig-
gered by Vpu.
In HIV-1 particles, one of the major constituents of the
viral core is the product of the vpr gene. Association of
Vpr with particles is reliant on p6 (27, 35) so it is possible
that the p6-mediated particle release from Cos cells in-
volves the action of Vpr. To determine whether Vpr plays
a role in p6-mediated release of particles from Cos cells
we constructed a battery of vpr0 single, double, and triple
mutants. Mutations were introduced into pWT, pMS168,
pMS172, and pMS176 which create a stop codon after
amino acid 11 of Vpr. These mutant DNAs are designatedFIG. 5. Intracytoplasmic capsid formation assay. Cos or HeLa cells
pMS178 (p6/pr/vpr0), pMS177 (p60pr/vpr0), pMS179were transfected with pWT and 36 hr posttransfection cells were pulsed
labeled with L-[35S]methionine for 60 min and chased for various times. (p6/pr0vpr0), and pMS180 (p60pr0vpr0). We then trans-
Following the chase periods cells were lysed with Triton X-100 lysis fected these DNAs into Cos cells (Fig. 3A) or HeLa cells
buffer and subjected to centrifugation through a 30% sucrose cushion. (data not shown) and analyzed cytoplasmic protein ex-
The pellet and supernatant from the spins were then independently
pression and virus particle release by immunoblot analy-immunoprecipitated with a rabbit anti-Gag serum, subjected to 10%
sis. All of the Vpr0 mutant DNAs expressed the GagSDS –PAGE, and visualized by phosphorimage analysis. Media from
cells of the 90-min chase were also subjected to the same virus isola- proteins anticipated from their genotype. Moreover, the
tion and immunoprecipitation protocol to demonstrate that this proce- absence of Vpr had no detectable effect in any of the
dure is appropriate for the isolation of HIV-1 particles (media). alternative genetic backgrounds (Fig. 3A and data not
shown). Thus, Vpr is unlikely to function in p6-mediated
particle release.Cos and HeLa cells the majority of the viral protein is
found in the soluble fraction, suggesting that intracellular Our results indicate that p6 is required for efficient
virus particle release from Cos cells but that it is dispen-particles do not form efficiently (Fig. 5). These results are
consistent with coupled particle assembly and release sible for this event in HeLa and Jurkat cells. These find-
ings are in agreement with other studies which demon-at the cell surface, a mode typical for type-C and lentivi-
ruses rather than type-D retroviruses. When medium from strate a requirement for p6 for the efficient release of
virus particle from Cos cells (24). However, our findingtransfected cells was subjected to the same assay as
the cell lysates, we found that fully processed p24 can that p6 is not required for efficient virus particle release
from HeLa cells differs from the results of a previousbe pelleted, indicating that the conditions used for frac-
tionation of soluble and insoluble viral protein from within study (26). Huang et al. (26) found that p6 is required
for efficient virus particle release from HeLa cells. Onecells are appropriate for the isolation of HIV-1 particles
(Fig. 5, media). possible explanation for this discrepency is that in their
study the viral proteins are produced in the context of aIn addition to facilitating particle release from HeLa
cells, Vpu promotes the degradation of CD4 in HeLa full-length, infectious HIV-1 molecular clone. Studies
which indicate that p6 is not required express viral pro-cells (11, 12). Evidence to date indicates that these two
activities are separate. However, since Vpu was not re- teins from a system other than a full-length, infectious
HIV-1 molecular clone (27–31, 33, 34). Our system ex-quired for efficient release from Cos cells we wanted to
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presses viral proteins from a noninfectious HIV-1 molecu- p6. A variation of this basic scheme is that the rate-
lar clone containing a deletion in the env gene. limiting step in particle egress might vary in alternative
Huang et al. (26) also demonstrated that virus con- cell lines. In HeLa and Jurkat cells, the Vpu-dependent
taining mutations in the PTAP motif of p6 are efficiently step would be rate limiting in the absence of Vpu, while
released from HeLa cells when proteolytic processing of in Cos cells the p6-dependent step would be rate limiting
Gag does not occur. In our system we find that proteolytic when p6 is absent.
processing of Gag does not significantly affect the phe- Our genetic data indicate that the activities of Vpu and
notype of a p6 deletion in Cos cells. Since we do not p6 are not antagonistic and are consistent with the idea
see an altered phenotype for a p6 deletion in HeLa cells, that both Vpu and p6 are positive factors that promote
it is difficult to draw conclusions regarding the role of particle release. There are two relatively simple ways
proteolytic processing on a p6 deletion in HeLa cells. to account for the cell line difference in Vpu-dependent
However, in Cos cells the lack of a significant effect of particle release. First, a specific cellular factor may be
proteolytic processing on a p6 deletion in our system present in Cos cells that has a Vpu-like activity, thereby
could be explained by the differences in the p6 mutations obviating the need for Vpu in particle release. A second
between these two studies. Huang et al. (26) reported possibility is that HeLa and Jurkat cells express a factor
the effect of proteolytic processing on the efficiency of that negatively affects particle release and that Cos cells
release of virus particles containing mutations in the lack this factor. Vpu would then be required to counteract
PTAP motif, while we studied the effect of proteolytic that negative factor in HeLa and Jurkat cells. Two comple-
processing on the efficiency of release of virus particles mentary, and similar, possibilities can be invoked to ac-
containing a p6 deletion. Either the effect of proteolytic count for the cell line difference in p6-dependent virus
processing on the efficiency of release of particles con- exit.
taining p6 mutations from Cos cells is not significant, Vpu-mediated CD4 degradation occurs in both Cos
since we see only a modest increase in the efficiency of and HeLa cells. If Vpu interacts with cellular factors to
virus particle release from pMS176 (Figs. 3A and 3C), or mediate CD4 degradation then those cellular factors
the effect of proteolytic processing on p6 mutations is must be common to both Cos and HeLa cells. These
not manifested when the entire p6 domain is deleted. data also reinforce the idea that the two activities of Vpu
We also observe an alteration in the extent of proteo- are mechanistically separate (42).
lytic processing of virus particles containing p6 deletions
Vpr is a protein found in particles that plays a role in
in both HeLa and Cos cells. This alteration is evident
viral replication by facilitating transport of the viral DNA –
by the increased amount of p41 (MA-CA) and p25 (CA
protein complex across the nuclear membrane (40). Inintermediate). In addition, virus particles containing a p6
addition, Vpr appears to affect the progression of cellsdeletion have a decreased p24/pr55 ratio (data not
through the cell cycle, an activity not clearly linked toshown). This alteration in proteolytic processing could
replication (43, 44). Vpr is incorporated into particles bybe due to a direct effect of p6 on HIV-1 PR or, more likely,
direct or indirect interaction with the p6 domain of Gag.the deletion or mutation of p6 could affect the overall
On the other hand, our results suggest that Vpr plays noconformation of pr55, resulting in the observed pro-
role in p6-mediated particle release. Thus, the two rolescessing alteration.
of the p6 domain of Gag (to augment particle releaseThe most straightforward explanation for our results
and to allow association of Vpr with particles) do notis that there is a cell-specific difference that renders Vpu
appear to be directly related.and p6 dispensable for particle release from Cos and
Our initial experiments that examined particle releaseHeLa (Jurkat) cells, respectively. There are two general
were predicated on the hypothesis that HIV-1 acquiredmodels by which this could occur. First, there could be
a vpu gene to more successfully replicate in human cells.two distinct pathways that lead to release of HIV-1 parti-
However, we do not yet know whether the cell line differ-cles from cells, one being Vpu-dependent and the other
ence we observed with HeLa, Jurkat, and Cos cells isbeing p6-dependent. The dominant pathway would then
uniformly applicable to other simian and human cells.be different in Cos and HeLa cells. We determined by
SIV can replicate in human cells. However, replicationthe intracytoplasmic capsid formation assay that there is
is accompanied by selection for variants that encode anot a gross difference in the assembly of viral capsids
truncated Env glycoprotein (45). Moreover, a recent re-between Cos and HeLa cells. It appears that virus as-
port indicates that p6 is not absolutely required for HIV-sembly and budding occur at the plasma membrane, the
1 particle release from African green monkey cells (BSC-hallmark of lenti- and type-C viruses in both cell lines.
40) (21). These observations suggest that the differenceThe second possibility is that Vpu and p6 function in
in particle release may not strictly correlate with the spe-distinct steps along a single pathway that leads to parti-
cies from which the cells arise. More stringent challengecle release. Cos cells could merely contain a factor that
of our hypothesis will require analysis of particle releasefunctionally substitutes for Vpu, while HeLa and Jurkat
cells contain a factor that obviates the requirement for from a battery of additional cell lines.
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